AstraZeneca Says Its COVID-19 Vaccine Candidate Is 70% Efficacious

Henrietta Brewer
November 23, 2020

How well it works: 70 per cent if given as two full doses a month apart.

It added: "One dosing regimen (n=2,741) showed vaccine efficacy of 90 per cent when AZD1222 was given as a half dose, followed by a full dose at least one month apart".

The Oxford University/AstraZeneca coronavirus vaccine is 70 per cent effective at preventing COVID-19 - 25 per cent lower that US-produced rivals, preliminary results have revealed today.

The findings indicate there were 131 COVID-19 cases in the trial sample, but there were no hospitalized or severe cases in anyone who received the vaccine.

No serious safety events related to the vaccine have been confirmed and it was well tolerated across both dosing regimens, the company added.

"Incredibly exciting news the Oxford vaccine has proved so effective in trials".

Mr Soriot said: "This vaccine's efficacy and safety confirm that it will be highly effective against Covid-19 and will have an immediate impact on this public health emergency. Furthermore, the vaccine's simple supply chain and our no-profit pledge and commitment to broad, equitable and timely access means it will be affordable and globally available, supplying hundreds of millions of doses on approval".

Earlier on Monday, the Oxford-AstraZeneca team announced that one of the dosing regimens of the vaccine might be 90% effective in preventing COVID-19 infection.

It said the vaccine can be stored, transported and handled "at normal refrigerated conditions" of between two and eight degrees Celsius for at least six months.

The data comes after United States rivals published interim data in recent weeks showing efficacy of more than 90%.

"Importantly, from what we have heard the vaccine seems to prevent infection not just disease". Researchers have previously said these details could become clear only after the vaccine candidates' phase 3 clinical trials are complete. So when we give a half dose as the first dose (it) means that we've got more vaccine available.

"The results from this trial of the Oxford/AZ vaccine are highly encouraging, demonstrating significant efficacy".

An emergency authorisation of the coronavirus vaccine would ensure its proper administration based on the priority list, starting with frontline workers, senior citizens, people with comorbidities and so on.

Compared to the Moderna and Pfizer-BioNTech vaccine candidates, the efficiency of the Oxford-AstraZeneca vaccine candidate is low but this is only after the initial reports.

Other reports by iNewsToday